AZ-VUB
18
1
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
16.7%
3 terminated/withdrawn out of 18 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
Role: lead
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
Role: collaborator
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
Role: collaborator
MSC and HSC Coinfusion in Mismatched Minitransplants
Role: collaborator
Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer
Role: lead
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation
Role: lead
The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases
Role: collaborator
Bet Cell Therapy in Diabetes Type 1
Role: lead
Beta Cell Function in (Pre)Type 1 Diabetes
Role: lead
Long-term Function of Beta Cell Allografts in Non-uremic Type 1 Diabetic Patients
Role: lead
Beta Cell Function in (Pre) Type 1 Diabetes
Role: lead
Extension of Phase II Therapeutic Trial With a Humanized Non-Mitogenic CD3 (ChAgly CD3) Monoclonal Antibody in Recently Diagnosed Type 1 Diabetic Patients
Role: lead
Protocol for Primary Fractionated Stereotactic Body Radiation Therapy for Stage T1 - T3N0 Non Small Cell Lung Carcinoma.
Role: lead
Prevention of Clinical Onset of Type 1 Diabetes in High Risk First Degree Relatives
Role: lead
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Role: lead
Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes
Role: lead
Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts
Role: lead
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Role: lead
All 18 trials loaded